Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Aspergillosis | 15 | 2023 | 47 | 8.360 |
Why?
|
Uganda | 58 | 2024 | 1332 | 4.380 |
Why?
|
Antifungal Agents | 16 | 2024 | 752 | 3.580 |
Why?
|
Aspergillus | 9 | 2024 | 94 | 2.700 |
Why?
|
Aspergillosis | 7 | 2024 | 242 | 2.410 |
Why?
|
Mycoses | 6 | 2024 | 386 | 2.410 |
Why?
|
Tuberculosis, Pulmonary | 8 | 2024 | 830 | 2.090 |
Why?
|
Itraconazole | 5 | 2024 | 43 | 1.730 |
Why?
|
Tuberculosis | 8 | 2024 | 2017 | 1.690 |
Why?
|
Tuberculosis, Multidrug-Resistant | 5 | 2024 | 934 | 1.560 |
Why?
|
Tinea Capitis | 2 | 2020 | 15 | 1.460 |
Why?
|
Antibodies, Fungal | 5 | 2024 | 34 | 1.390 |
Why?
|
Hospitals, Teaching | 5 | 2024 | 1155 | 1.390 |
Why?
|
Autopsy | 2 | 2024 | 1010 | 1.390 |
Why?
|
Onychomycosis | 2 | 2022 | 50 | 1.370 |
Why?
|
Health Knowledge, Attitudes, Practice | 7 | 2024 | 4014 | 1.290 |
Why?
|
Africa | 10 | 2024 | 714 | 1.220 |
Why?
|
HIV Infections | 18 | 2024 | 17348 | 1.080 |
Why?
|
Antitubercular Agents | 6 | 2024 | 1374 | 1.060 |
Why?
|
Immunoglobulin G | 7 | 2024 | 4537 | 1.040 |
Why?
|
Health Personnel | 3 | 2024 | 3337 | 0.960 |
Why?
|
Trichophyton | 2 | 2022 | 20 | 0.950 |
Why?
|
Immunoglobulin M | 4 | 2024 | 1527 | 0.950 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2023 | 662 | 0.940 |
Why?
|
Prevalence | 24 | 2024 | 15721 | 0.890 |
Why?
|
Hemorrhagic Fevers, Viral | 1 | 2023 | 23 | 0.850 |
Why?
|
Candidiasis, Vulvovaginal | 1 | 2022 | 25 | 0.810 |
Why?
|
Wilms Tumor | 2 | 2023 | 376 | 0.780 |
Why?
|
Cross-Sectional Studies | 32 | 2024 | 26072 | 0.780 |
Why?
|
Cryptococcosis | 2 | 2024 | 103 | 0.780 |
Why?
|
Hypertriglyceridemia | 1 | 2024 | 292 | 0.730 |
Why?
|
Hyperphagia | 1 | 2021 | 139 | 0.730 |
Why?
|
Ebolavirus | 1 | 2023 | 247 | 0.700 |
Why?
|
Horner Syndrome | 1 | 2020 | 35 | 0.690 |
Why?
|
Peptic Ulcer Perforation | 1 | 2019 | 22 | 0.690 |
Why?
|
Tuberculosis, Meningeal | 1 | 2020 | 47 | 0.670 |
Why?
|
Living Donors | 1 | 2024 | 643 | 0.660 |
Why?
|
Contact Tracing | 1 | 2022 | 272 | 0.660 |
Why?
|
Dyslipidemias | 2 | 2024 | 870 | 0.660 |
Why?
|
Refugees | 2 | 2024 | 595 | 0.650 |
Why?
|
Diabetes Mellitus | 5 | 2024 | 5842 | 0.650 |
Why?
|
Aspergillus nidulans | 1 | 2018 | 8 | 0.650 |
Why?
|
Triazoles | 3 | 2019 | 902 | 0.640 |
Why?
|
Aspergillus flavus | 1 | 2018 | 14 | 0.640 |
Why?
|
Drug Resistance, Fungal | 2 | 2023 | 76 | 0.640 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2019 | 168 | 0.630 |
Why?
|
Aspergillus fumigatus | 2 | 2021 | 157 | 0.610 |
Why?
|
Hospitals, University | 1 | 2020 | 565 | 0.600 |
Why?
|
Self-Injurious Behavior | 1 | 2024 | 566 | 0.590 |
Why?
|
Universities | 3 | 2023 | 995 | 0.590 |
Why?
|
Mediastinal Neoplasms | 1 | 2021 | 401 | 0.590 |
Why?
|
Malnutrition | 1 | 2024 | 622 | 0.590 |
Why?
|
Teratoma | 1 | 2021 | 404 | 0.590 |
Why?
|
Informed Consent | 1 | 2024 | 1008 | 0.580 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2023 | 419 | 0.580 |
Why?
|
Dental Caries | 1 | 2021 | 427 | 0.570 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2019 | 219 | 0.570 |
Why?
|
Fluconazole | 1 | 2018 | 156 | 0.570 |
Why?
|
Research Report | 1 | 2020 | 367 | 0.570 |
Why?
|
Cryptococcus neoformans | 1 | 2018 | 120 | 0.570 |
Why?
|
Contraceptive Agents | 1 | 2018 | 144 | 0.550 |
Why?
|
Humans | 108 | 2024 | 761222 | 0.550 |
Why?
|
Communicable Diseases, Emerging | 1 | 2017 | 148 | 0.520 |
Why?
|
Oral Health | 1 | 2021 | 491 | 0.520 |
Why?
|
Tissue and Organ Procurement | 1 | 2024 | 963 | 0.510 |
Why?
|
Students | 3 | 2023 | 1737 | 0.510 |
Why?
|
Candidiasis | 1 | 2018 | 365 | 0.500 |
Why?
|
Anemia | 2 | 2022 | 1504 | 0.500 |
Why?
|
Occupational Diseases | 1 | 2023 | 1490 | 0.500 |
Why?
|
Chronic Disease | 11 | 2023 | 9319 | 0.490 |
Why?
|
Mycology | 3 | 2024 | 13 | 0.490 |
Why?
|
Young Adult | 27 | 2024 | 59222 | 0.460 |
Why?
|
Adult | 47 | 2024 | 221120 | 0.450 |
Why?
|
Income | 2 | 2023 | 1869 | 0.440 |
Why?
|
Nitriles | 1 | 2019 | 971 | 0.440 |
Why?
|
Meta-Analysis as Topic | 3 | 2023 | 1381 | 0.430 |
Why?
|
Aspergillosis, Allergic Bronchopulmonary | 2 | 2024 | 12 | 0.430 |
Why?
|
Burnout, Professional | 1 | 2021 | 703 | 0.410 |
Why?
|
Female | 55 | 2024 | 392552 | 0.400 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5493 | 0.390 |
Why?
|
Weight Gain | 1 | 2021 | 2349 | 0.370 |
Why?
|
Adolescent | 21 | 2024 | 88300 | 0.360 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2019 | 2196 | 0.360 |
Why?
|
Microbial Sensitivity Tests | 4 | 2023 | 1936 | 0.360 |
Why?
|
Students, Medical | 2 | 2022 | 1940 | 0.350 |
Why?
|
Male | 46 | 2024 | 360703 | 0.350 |
Why?
|
Developing Countries | 3 | 2021 | 2863 | 0.350 |
Why?
|
Neglected Diseases | 2 | 2021 | 66 | 0.340 |
Why?
|
Histoplasmosis | 2 | 2021 | 63 | 0.340 |
Why?
|
Disease Management | 1 | 2020 | 2507 | 0.330 |
Why?
|
Isoniazid | 2 | 2021 | 283 | 0.320 |
Why?
|
Weight Loss | 1 | 2020 | 2680 | 0.320 |
Why?
|
Laparotomy | 2 | 2022 | 456 | 0.320 |
Why?
|
Quality of Life | 4 | 2021 | 13367 | 0.310 |
Why?
|
Retrospective Studies | 21 | 2024 | 80675 | 0.310 |
Why?
|
Hypertension | 3 | 2023 | 8536 | 0.310 |
Why?
|
Kidney Neoplasms | 2 | 2023 | 4251 | 0.300 |
Why?
|
Fungi | 4 | 2023 | 337 | 0.300 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4739 | 0.290 |
Why?
|
Immunoglobulin E | 3 | 2024 | 1505 | 0.280 |
Why?
|
Pyridines | 1 | 2019 | 2872 | 0.280 |
Why?
|
Histoplasma | 3 | 2023 | 39 | 0.260 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 1063 | 0.260 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4310 | 0.250 |
Why?
|
Diagnostic Tests, Routine | 3 | 2022 | 788 | 0.250 |
Why?
|
Pandemics | 4 | 2023 | 8663 | 0.250 |
Why?
|
International Cooperation | 2 | 2023 | 1423 | 0.240 |
Why?
|
Prenatal Care | 2 | 2024 | 1141 | 0.240 |
Why?
|
Middle Aged | 23 | 2024 | 220858 | 0.240 |
Why?
|
Schools, Medical | 2 | 2022 | 878 | 0.230 |
Why?
|
Invasive Pulmonary Aspergillosis | 1 | 2024 | 18 | 0.230 |
Why?
|
Azoles | 1 | 2023 | 22 | 0.220 |
Why?
|
Suicidal Ideation | 2 | 2024 | 1447 | 0.220 |
Why?
|
Helminths | 1 | 2023 | 39 | 0.220 |
Why?
|
Risk Factors | 12 | 2024 | 74241 | 0.220 |
Why?
|
Hepatitis B Vaccines | 1 | 2024 | 177 | 0.210 |
Why?
|
Mucormycosis | 1 | 2024 | 102 | 0.210 |
Why?
|
Helminthiasis | 1 | 2023 | 81 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.200 |
Why?
|
Antigens, Fungal | 2 | 2021 | 69 | 0.200 |
Why?
|
Child | 15 | 2024 | 80154 | 0.200 |
Why?
|
Meningitis, Cryptococcal | 2 | 2024 | 67 | 0.200 |
Why?
|
Serologic Tests | 1 | 2024 | 381 | 0.200 |
Why?
|
Students, Health Occupations | 1 | 2022 | 29 | 0.200 |
Why?
|
Drugs, Essential | 1 | 2022 | 71 | 0.200 |
Why?
|
Tumor Lysis Syndrome | 1 | 2021 | 38 | 0.190 |
Why?
|
Zenker Diverticulum | 1 | 2021 | 28 | 0.190 |
Why?
|
Candida | 1 | 2022 | 172 | 0.190 |
Why?
|
Nigeria | 2 | 2022 | 771 | 0.180 |
Why?
|
Mentors | 2 | 2023 | 663 | 0.180 |
Why?
|
Fetal Weight | 1 | 2021 | 87 | 0.180 |
Why?
|
Pregnancy | 8 | 2024 | 29893 | 0.180 |
Why?
|
Lung Diseases, Fungal | 1 | 2021 | 125 | 0.180 |
Why?
|
Private Sector | 1 | 2024 | 394 | 0.180 |
Why?
|
Ethiopia | 1 | 2022 | 461 | 0.180 |
Why?
|
Mycetoma | 1 | 2020 | 18 | 0.170 |
Why?
|
Echinocandins | 1 | 2020 | 53 | 0.170 |
Why?
|
Term Birth | 1 | 2021 | 140 | 0.170 |
Why?
|
Retreatment | 1 | 2022 | 598 | 0.170 |
Why?
|
Ethambutol | 1 | 2020 | 59 | 0.170 |
Why?
|
Sensitivity and Specificity | 4 | 2023 | 14675 | 0.170 |
Why?
|
Hemoptysis | 1 | 2021 | 151 | 0.170 |
Why?
|
Pyrazinamide | 1 | 2020 | 60 | 0.170 |
Why?
|
Sputum | 2 | 2021 | 505 | 0.170 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15521 | 0.170 |
Why?
|
Immunocompetence | 1 | 2020 | 138 | 0.170 |
Why?
|
Pyridoxine | 1 | 2020 | 108 | 0.170 |
Why?
|
Mediastinum | 1 | 2021 | 267 | 0.170 |
Why?
|
Reference Standards | 1 | 2023 | 1005 | 0.160 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2021 | 204 | 0.160 |
Why?
|
Candida albicans | 1 | 2022 | 372 | 0.160 |
Why?
|
Referral and Consultation | 3 | 2022 | 3608 | 0.160 |
Why?
|
Nuts | 1 | 2021 | 264 | 0.160 |
Why?
|
Algorithms | 1 | 2019 | 14025 | 0.160 |
Why?
|
Neoplasms | 3 | 2023 | 22142 | 0.160 |
Why?
|
Diabetic Neuropathies | 1 | 2022 | 406 | 0.160 |
Why?
|
Burkitt Lymphoma | 1 | 2021 | 335 | 0.160 |
Why?
|
Public Health | 2 | 2023 | 2672 | 0.160 |
Why?
|
Diabetic Foot | 1 | 2022 | 379 | 0.160 |
Why?
|
Amphotericin B | 1 | 2018 | 141 | 0.150 |
Why?
|
Hepatitis B | 1 | 2024 | 703 | 0.150 |
Why?
|
Aged, 80 and over | 9 | 2022 | 58952 | 0.150 |
Why?
|
Thinness | 1 | 2022 | 481 | 0.150 |
Why?
|
Rifampin | 1 | 2020 | 338 | 0.150 |
Why?
|
Immunoenzyme Techniques | 1 | 2021 | 1703 | 0.150 |
Why?
|
Abortion, Induced | 1 | 2024 | 462 | 0.150 |
Why?
|
Suicide, Attempted | 2 | 2024 | 1402 | 0.150 |
Why?
|
Aftercare | 1 | 2024 | 913 | 0.150 |
Why?
|
Immunoassay | 1 | 2021 | 743 | 0.140 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2020 | 330 | 0.140 |
Why?
|
Cholesterol, HDL | 1 | 2024 | 1812 | 0.140 |
Why?
|
Musculoskeletal Diseases | 1 | 2023 | 598 | 0.140 |
Why?
|
Genes, Fungal | 1 | 2018 | 439 | 0.140 |
Why?
|
Treatment Outcome | 6 | 2021 | 64681 | 0.140 |
Why?
|
Recurrence | 2 | 2021 | 8457 | 0.140 |
Why?
|
Home Care Services | 1 | 2023 | 647 | 0.140 |
Why?
|
Microscopy | 2 | 2023 | 904 | 0.140 |
Why?
|
Microbiological Techniques | 1 | 2017 | 97 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 3 | 2024 | 3200 | 0.140 |
Why?
|
Cost of Illness | 3 | 2020 | 1936 | 0.140 |
Why?
|
Contraception Behavior | 1 | 2018 | 180 | 0.130 |
Why?
|
Retinal Diseases | 1 | 2022 | 705 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2023 | 654 | 0.130 |
Why?
|
Adolescent Behavior | 1 | 2024 | 1188 | 0.130 |
Why?
|
Deglutition Disorders | 1 | 2021 | 627 | 0.130 |
Why?
|
Cesarean Section | 1 | 2024 | 1399 | 0.120 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 931 | 0.120 |
Why?
|
Eosinophils | 1 | 2020 | 951 | 0.120 |
Why?
|
Anti-Infective Agents | 1 | 2022 | 983 | 0.120 |
Why?
|
Causality | 1 | 2021 | 1244 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2023 | 1052 | 0.120 |
Why?
|
Metformin | 1 | 2022 | 910 | 0.120 |
Why?
|
Aged | 11 | 2024 | 169292 | 0.120 |
Why?
|
Pneumonectomy | 1 | 2021 | 1118 | 0.120 |
Why?
|
Organ Transplantation | 1 | 2024 | 1165 | 0.110 |
Why?
|
Tanzania | 1 | 2018 | 1390 | 0.110 |
Why?
|
Rural Population | 1 | 2024 | 2277 | 0.110 |
Why?
|
Survivors | 1 | 2024 | 2369 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1747 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1302 | 0.110 |
Why?
|
Mass Vaccination | 1 | 2014 | 109 | 0.100 |
Why?
|
Adaptation, Psychological | 1 | 2023 | 2632 | 0.100 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 1757 | 0.100 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.100 |
Why?
|
Birth Weight | 1 | 2021 | 2104 | 0.100 |
Why?
|
Administration, Oral | 1 | 2020 | 4015 | 0.100 |
Why?
|
Endoscopy | 2 | 2021 | 1852 | 0.100 |
Why?
|
Lung Transplantation | 1 | 2021 | 1307 | 0.100 |
Why?
|
Schools | 1 | 2020 | 1483 | 0.100 |
Why?
|
Peripheral Arterial Disease | 1 | 2022 | 1275 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3149 | 0.090 |
Why?
|
Health Occupations | 2 | 2022 | 223 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2022 | 7804 | 0.090 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1784 | 0.090 |
Why?
|
Radiography | 1 | 2021 | 6974 | 0.080 |
Why?
|
Emotions | 1 | 2021 | 2742 | 0.080 |
Why?
|
Blood Glucose | 1 | 2024 | 6392 | 0.080 |
Why?
|
Critical Illness | 1 | 2022 | 2724 | 0.080 |
Why?
|
Genetic Loci | 1 | 2018 | 2623 | 0.080 |
Why?
|
Kidney | 1 | 2024 | 7033 | 0.080 |
Why?
|
Postoperative Complications | 2 | 2022 | 15637 | 0.080 |
Why?
|
Liver | 1 | 2024 | 7512 | 0.080 |
Why?
|
Intensive Care Units | 1 | 2022 | 3744 | 0.080 |
Why?
|
Laboratories | 2 | 2023 | 462 | 0.080 |
Why?
|
Mass Screening | 2 | 2021 | 5426 | 0.080 |
Why?
|
Stress, Psychological | 1 | 2023 | 4487 | 0.080 |
Why?
|
Papillomavirus Vaccines | 1 | 2014 | 496 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2684 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2022 | 12159 | 0.070 |
Why?
|
Poverty | 1 | 2019 | 2691 | 0.070 |
Why?
|
Ambulatory Care | 1 | 2018 | 2770 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7407 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3610 | 0.070 |
Why?
|
Body Weight | 1 | 2018 | 4618 | 0.070 |
Why?
|
Depression | 2 | 2024 | 8132 | 0.070 |
Why?
|
Logistic Models | 1 | 2022 | 13249 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13386 | 0.070 |
Why?
|
Research Design | 1 | 2023 | 6180 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20588 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2021 | 3417 | 0.070 |
Why?
|
Prospective Studies | 5 | 2023 | 54437 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4021 | 0.070 |
Why?
|
Diet | 1 | 2024 | 8048 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2018 | 1923 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12976 | 0.070 |
Why?
|
Epilepsy | 1 | 2021 | 3304 | 0.060 |
Why?
|
Hospitals | 3 | 2023 | 3881 | 0.060 |
Why?
|
Cognition | 1 | 2022 | 6988 | 0.060 |
Why?
|
Fetal Distress | 1 | 2024 | 39 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 2 | 2021 | 2570 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2022 | 6341 | 0.060 |
Why?
|
Labor Presentation | 1 | 2024 | 55 | 0.060 |
Why?
|
Inflammation | 1 | 2024 | 10759 | 0.060 |
Why?
|
Animals | 4 | 2023 | 168089 | 0.060 |
Why?
|
Agar | 1 | 2023 | 51 | 0.060 |
Why?
|
Sudan | 1 | 2023 | 86 | 0.060 |
Why?
|
Obesity | 2 | 2022 | 12940 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5321 | 0.050 |
Why?
|
Prednisolone | 1 | 2024 | 324 | 0.050 |
Why?
|
Private Practice | 1 | 2024 | 152 | 0.050 |
Why?
|
Aspartate Aminotransferases | 1 | 2024 | 411 | 0.050 |
Why?
|
United Nations | 1 | 2023 | 148 | 0.050 |
Why?
|
Soil | 1 | 2023 | 116 | 0.050 |
Why?
|
Apgar Score | 1 | 2022 | 126 | 0.050 |
Why?
|
Sex Factors | 3 | 2021 | 10553 | 0.050 |
Why?
|
Asthma | 1 | 2021 | 6230 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2014 | 1616 | 0.050 |
Why?
|
Glyburide | 1 | 2022 | 116 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2014 | 2019 | 0.050 |
Why?
|
Alanine Transaminase | 1 | 2024 | 602 | 0.050 |
Why?
|
Infant | 2 | 2021 | 36170 | 0.050 |
Why?
|
Viral Load | 2 | 2021 | 3328 | 0.050 |
Why?
|
Alkaline Phosphatase | 1 | 2024 | 859 | 0.050 |
Why?
|
Cameroon | 1 | 2021 | 78 | 0.050 |
Why?
|
Spirometry | 1 | 2024 | 928 | 0.050 |
Why?
|
Parity | 1 | 2024 | 929 | 0.050 |
Why?
|
Kenya | 1 | 2024 | 756 | 0.050 |
Why?
|
Child, Preschool | 2 | 2021 | 42225 | 0.050 |
Why?
|
Maternal Mortality | 1 | 2024 | 301 | 0.050 |
Why?
|
Family Planning Services | 1 | 2024 | 267 | 0.050 |
Why?
|
Actinomycetaceae | 1 | 2020 | 5 | 0.040 |
Why?
|
Nocardia | 1 | 2020 | 9 | 0.040 |
Why?
|
Tropical Climate | 1 | 2020 | 35 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2024 | 527 | 0.040 |
Why?
|
Cardiomegaly | 1 | 2023 | 590 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2023 | 745 | 0.040 |
Why?
|
North America | 1 | 2023 | 1284 | 0.040 |
Why?
|
Respiratory Function Tests | 1 | 2024 | 1685 | 0.040 |
Why?
|
Obesity, Abdominal | 1 | 2022 | 373 | 0.040 |
Why?
|
Fungal Proteins | 1 | 2023 | 908 | 0.040 |
Why?
|
Incidence | 3 | 2024 | 21366 | 0.040 |
Why?
|
Laboratories, Hospital | 1 | 2020 | 192 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2024 | 12474 | 0.040 |
Why?
|
Body Size | 1 | 2021 | 463 | 0.040 |
Why?
|
Pilot Projects | 2 | 2021 | 8642 | 0.040 |
Why?
|
Program Development | 1 | 2023 | 1294 | 0.040 |
Why?
|
Attitude | 1 | 2022 | 771 | 0.040 |
Why?
|
Body Temperature | 1 | 2020 | 780 | 0.030 |
Why?
|
Area Under Curve | 1 | 2021 | 1636 | 0.030 |
Why?
|
Infant, Newborn | 3 | 2022 | 26200 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1664 | 0.030 |
Why?
|
Gestational Age | 1 | 2024 | 3580 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2022 | 1048 | 0.030 |
Why?
|
Program Evaluation | 1 | 2023 | 2489 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2021 | 2359 | 0.030 |
Why?
|
Lung Diseases | 1 | 2024 | 1910 | 0.030 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7400 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 2021 | 1265 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3584 | 0.030 |
Why?
|
Brain | 1 | 2020 | 27094 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 3024 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6067 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2545 | 0.020 |
Why?
|
Lipids | 1 | 2022 | 3331 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3803 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2022 | 6486 | 0.020 |
Why?
|
Critical Care | 1 | 2023 | 2696 | 0.020 |
Why?
|
Outpatients | 1 | 2018 | 1598 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5250 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5869 | 0.020 |
Why?
|
Seizures | 1 | 2022 | 2965 | 0.020 |
Why?
|
Anxiety | 1 | 2023 | 4569 | 0.020 |
Why?
|
Insulin | 1 | 2022 | 6588 | 0.020 |
Why?
|
Survival Rate | 1 | 2022 | 12728 | 0.020 |
Why?
|
Blood Pressure | 1 | 2023 | 8479 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14610 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22174 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16575 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5426 | 0.020 |
Why?
|
Hospitalization | 1 | 2024 | 10707 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18384 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9278 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 29688 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41496 | 0.010 |
Why?
|
Concepts
(335)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_